Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

Jennifer K. Litton*, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalves, Kyung Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martin, Henri Roché, Young Hyuck Im, Ruben G.W. Quek, Denka Markova, Iulia C. Tudor, Alison L. Hannah, Wolfgang Eiermann, Joanne L. Blum

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


BACKGROUND The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 (BRCA1/2). METHODS We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio to receive talazoparib (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy. Median progressionfree survival was significantly longer in the talazoparib group than in the standardtherapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001). The interim median hazard ratio for death was 0.76 (95% CI, 0.55 to 1.06; P = 0.11 [57% of projected events]). The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001). Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively. Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clinically meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were observed. CONCLUSIONS Among patients with advanced breast cancer and a germline BRCA1/2 mutation single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775.)

Original languageEnglish
Pages (from-to)753-763
Number of pages11
JournalNew England Journal of Medicine
Issue number8
StatePublished - 23 Aug 2018
Externally publishedYes


FundersFunder number


    Dive into the research topics of 'Talazoparib in patients with advanced breast cancer and a germline BRCA mutation'. Together they form a unique fingerprint.

    Cite this